After falling more than 6 dollars since May of this year. Keep an eye out.
XTL Biopharmaceuticals engages in the acquisition, development, and commercialization of pharmaceutical products for the treatment of infectious diseases. The company focuses on the prevention and treatment of hepatitis B and C. They have a current pipeline of XTL-2125, a small molecule non-nucleoside, polymerase inhibitor for the treatment of patients with hepatitis C, is under phase I clinical trail; XTL-6865, which is under Phase Ia clinical trial for the treatment of patients with hepatitis C virus to prevent the infection of healthy liver cells.
Polymerase inhibitors stop the action of enzymes in the virus from making new proteins from DNA and to stop the virus from replicating.
XTL-6865 is a mixture of antibodies to proteins on the viral surface: XTL-6865 is being developed to prevent HCV re-infection following a liver transplant and for the treatment of chronic HCV disease. XTL-6865 is a combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis C virus E2 envelope protein. A single antibody version of this product was tested in a pilot clinical program that included both Phase I and Phase II clinical trials and provided preliminary evidence of anti-viral activity in humans.
XTL trades on the NASDAQ index under the symbol XTLB.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment